Baxter’s War Games: Post-Heparin, Scientists Consider Supply Chain Threats
This article was originally published in PharmAsia News
Executive Summary
Part of Baxter's response to its heparin contamination fiasco has been to bring its scientists together to imagine ways counterfeiters could infiltrate its supply chain and how they would be countered.
You may also be interested in...
Baxter Expanding Facilities In China To Keep Pace With Exploding Market Growth, Testing A/H1N1 Strain In U.S. For Potential Vaccine
BEIJING - The U.S.-headquartered Baxter International is reinvesting most of the $200 million in revenues it posted in China in 2008 to expand production facilities across the country, even as Baxter's American scientists begin testing a strain of the A/H1N1 virus for a potential vaccine if a pandemic is declared by the World Health Organization
Baxter Expanding Facilities In China To Keep Pace With Exploding Market Growth, Testing A/H1N1 Strain In U.S. For Potential Vaccine
BEIJING - The U.S.-headquartered Baxter International is reinvesting most of the $200 million in revenues it posted in China in 2008 to expand production facilities across the country, even as Baxter's American scientists begin testing a strain of the A/H1N1 virus for a potential vaccine if a pandemic is declared by the World Health Organization
Parexel Consulting Corporate VP Alberto Grignolo On Conducting Clinical Trials In China, India And Asia: An Interview With PharmAsia News
Parexel Consulting Corporate VP Alberto Grignolo recently spoke with PharmAsia News about Asia's evolving clinical trial environment - including the launch of U.S. FDA offices in Asia and the prospect of multinational companies conducting Phase I trials in India. Parexel works with life sciences companies to create clinical development strategies as well as Good Clinical Practices and Good Manufacturing Practices compliance.